Pediatrix Medical Group, Inc.
NYSE•MD
CEO: Mr. Mark S. Ordan
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 1995-09-20
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
Contact Information
Market Cap
$1.68B
P/E (TTM)
10.0
16.3
Dividend Yield
--
52W High
$24.99
52W Low
$11.84
52W Range
Rank46Top 59.5%
3.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$493.77M+0.00%
4-Quarter Trend
EPS
$0.40+0.00%
4-Quarter Trend
FCF
$108.82M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Income Rebounds Strongly Net income reached $165.4M in 2025, reversing $99.1M loss in 2024; same-unit revenue grew 6.2%.
Operations Swing to Profitability Income from operations was $208.8M (10.9% margin) in 2025, a major improvement from $68.7M loss last year.
Strategic Acquisitions Completed Acquired multiple practices including maternal-fetal and neonatology groups during 2025, expanding core specialty footprint.
Cash Position Significantly Improved Cash and equivalents increased to $375.2M by year-end 2025, up $145.3M from prior year levels.
Risk Factors
Medicaid Reimbursement Uncertainty Reimbursement relies heavily on GHC Programs; state budgetary constraints and reform efforts pose ongoing adverse effects.
Past Goodwill Impairment Risk Recorded $150.6M non-cash goodwill impairment in 2024 due to sustained stock price decline; future risk remains.
Litigation and Malpractice Exposure Inherent risk from malpractice claims; self-insurance reserves are subject to complex actuarial estimates and potential shortfalls.
Declining US Birth Rates Future patient volumes face risk from declining US birth rates, potentially impacting revenue growth across services.
Outlook
Focus on Core Specialty Growth Strategy centers on hospital-based and maternal-fetal medicine; exited office-based practices finalized in 2024.
Technology Integration Efforts Continued investment in technology like BabySteps, achieving initial HITRUST certification for core clinical applications.
Managing Debt Structure Total debt principal reduced to $596.9M by 2025; managing variable rate debt exposure remains key focus.
Operational Efficiency Improvements Transformation efforts target reducing administrative expenses and improving revenue cycle management efficiency post-outsourcing.
Peer Comparison
Revenue (TTM)
$6.32B
$6.22B
$5.45B
Gross Margin (Latest Quarter)
165.5%
82.9%
67.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| NHC | $2.51B | 20.8 | 11.6% | 5.7% |
| LFST | $2.47B | 252.9 | 0.7% | 8.8% |
| ACHC | $2.17B | -1.9 | -39.4% | 48.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.5%
Moderate Growth
4Q Net Income CAGR
17.5%
Profitability Improved
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:Apr 30, 2026
EPS:$0.38
|Revenue:$466.75M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data